About

Novan, Inc. is a medical dermatology company primarily focused on researching, developing and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. We are developing SB206 (berdazimer gel 10.3%) as a topical prescription gel for the treatment of viral skin infections, with current emphasis on molluscum contagiosum.

 

We recently completed the acquisition of EPI Health. EPI Health equips us with a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams. Following the acquisition, we employ approximately 100 staff, including sales personnel currently covering 42 territories, and we promote products for psoriasis, rosacea, acne and dermatoses. We also have a pipeline of potential product candidates using our proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.

NOVAN PRIDE UNDERPINS OUR EFFORTS

 

Performance

We are empowered to take ownership and provide quality outcomes and timely deliverables

Respectful

We are collaborative, we participate in active listening and support an open dialogue

Innovative

We are responsive to our science, and are open to new perspectives and ideas in all that we do

Dynamic

We are intentional in managing change, and we are responsive to our business, employees, and patient needs

Engaged

We are committed and dedicated to working together to improve patients’ lives

Novan, Inc. is a specialty dermatology company focused on researching, developing and marketing innovative therapeutic products for skin diseases. Through our acquisition of EPI Health, we sell products for acne, rosacea, dermatosis, and psoriasis. Our goal is to deliver safe and efficacious therapies where there are unmet medical needs. We are developing SB206 (berdazimer gel 10.3%) as a topical prescription gel for the treatment of viral skin infections, with a current focus on molluscum contagiosum. We have a pipeline of product candidates using our proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.

NOVAN PRIDE UNDERPINS OUR EFFORTS

 

Performance

We are empowered to take ownership and provide quality outcomes and timely deliverables

Respectful

We are collaborative, we participate in active listening and support an open dialogue

Innovative

We are responsive to our science, and are open to new perspectives and ideas in all that we do

Dynamic

We are intentional in managing change, and we are responsive to our business, employees, and patient needs

Engaged

We are committed and dedicated to working together to improve patients’ lives

Management Team

Our Science

Our Pipeline

Sign Up For Alerts